EXHIBIT 10.9 *CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS Memorandum of Understanding Supply and Services Agreement for...Memorandum of Understanding • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations
MASTER SERVICES AGREEMENTMaster Services Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations
This Master Service Agreement (the “Agreement”), made this 17th day of January, 2003 (the “Effective Date”), by and between PPD Development, LP, a Texas limited partnership, with its principal executive offices located at 3151 South 17th Street, Wilmington, North Carolina 28412 (“PPD”) and Corcept with its principal executive offices located at 275 Middlefield Road, Suite A, Menlo Park, California 94025 (“Sponsor”).
RESEARCH AGREEMENT/ cGMP MANUFACTURINGResearch Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
This agreement is entered into by and between KP Pharmaceutical Technology, Inc., 1212 Rappel Drive, Bloomington 47404 hereinafter called “Research Organization”, and Corcept Therapeutics Incorporated a corporation with its principal office and place of business at 275 Middlefield Road, Suite A, Menlo Park, CA 94025, hereinafter called “Sponsor”.
Shares CORCEPT THERAPEUTICS INCORPORATED COMMON STOCK UNDERWRITING AGREEMENT DatedUnderwriting Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
Introduction. Corcept Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”), and a stockholder of the Company (the “Selling Stockholder”) named in Schedule B hereto severally propose to sell to the several Underwriters, an aggregate of shares of the common stock, par value $.001 per share, of the Company (the “Firm Shares”), of which shares are to be issued and sold by the Company and shares are to be sold by the Selling Stockholder, with such Selling Stockholder selling the number of shares set forth in Schedule B hereto.
CORCEPT THERAPEUTICS INCORPORATED AMENDMENT NO. 1 TO AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENTInformation and Registration Rights Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT (the “Amendment”) is made as of March 16, 2004 by and among Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and the persons and entities listed on the attached Exhibit A (collectively, the “Investors”).
